Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-005981
Filing Date
2025-08-12
Accepted
2025-08-12 16:56:52
Documents
64
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUN 2025 sunshine_i10q-063025.htm   iXBRL 10-Q 679139
2 CERTIFICATION sunshine_ex3101.htm EX-31.1 11215
3 CERTIFICATION sunshine_ex3102.htm EX-31.2 11201
4 CERTIFICATION sunshine_ex3201.htm EX-32.1 4579
10 GRAPHIC image_001.jpg GRAPHIC 6215
  Complete submission text file 0001683168-25-005981.txt   3986267

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sbfm-20250630.xsd EX-101.SCH 35067
6 XBRL CALCULATION FILE sbfm-20250630_cal.xml EX-101.CAL 48018
7 XBRL DEFINITION FILE sbfm-20250630_def.xml EX-101.DEF 148199
8 XBRL LABEL FILE sbfm-20250630_lab.xml EX-101.LAB 288129
9 XBRL PRESENTATION FILE sbfm-20250630_pre.xml EX-101.PRE 245629
66 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_i10q-063025_htm.xml XML 414899
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-330-0684
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41282 | Film No.: 251207625
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)